Literature DB >> 3031162

HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis.

D L Mann, F Lasane, M Popovic, L O Arthur, W G Robey, W A Blattner, M J Newman.   

Abstract

The addition of inactivated preparations of purified human T cell lymphotropic virus (HTLV-III) was found to inhibit normal human lymphocyte phytohemagglutinin (PHA)-induced blastogenesis but had no effect on concanavalin A (Con A), pokeweek mitogen, or allogeneic stimulation. The inhibition was concentration-dependent and also dependent on adding the virus preparation before or at the same time as PHA. The CD4 molecule is the receptor for HTLV-III binding. Immunopurified large envelope protein (gp120) from HTLV-III was found to bind to the CD4 molecule and also inhibited PHA-induced lymphocyte blastogenesis. These results suggest that the gp120 viral protein may alter immune function by binding to the CD4 molecule, which in turn serves as an "off" signal to lymphocyte response to PHA stimulation. Alternatively, by binding to the CD4 molecule, gp120 may interfere with the interaction of this molecule with class II histocompatibility antigens on accessory cells, thus selectively suppressing PHA response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3031162

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  The role of CD4+ lymphocytes in the activation of non-specific suppressor cells by antigen.

Authors:  H Stefanovic; C Izaguirre; L G Filion
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Regulation of the serine-base exchange enzyme system by CD4: effects of monoclonal antibodies, jacalin, interleukin 16 and the HIV membrane protein gp120.

Authors:  M J Dumaurier; C Pelassy; J P Breittmayer; C Aussel
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

5.  Depletion of the surface CD4 molecule by the envelope protein of human immunodeficiency virus expressed in a human CD4+ monocytoid cell line.

Authors:  I Kawamura; Y Koga; N Oh-Hori; K Onodera; G Kimura; K Nomoto
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.

Authors:  D A Dibbern; G W Glazner; I Gozes; D E Brenneman; J M Hill
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

7.  Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.

Authors:  B A Castro; C D Weiss; L D Wiviott; J A Levy
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

Review 8.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

9.  Repression of human immunodeficiency virus type 1 long terminal repeat-driven gene expression by binding of the virus to its primary cellular receptor, the CD4 molecule.

Authors:  P Bérubé; B Barbeau; R Cantin; R P Sékaly; M Tremblay
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.